A Phase I/II, Open-Label Study of Neratinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Neratinib (Primary) ; Capecitabine
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Puma Biotechnology
- 06 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 14 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017, as reported by ClinicalTrials.gov.